265 related articles for article (PubMed ID: 23998731)
1. Current immunotherapy in rheumatoid arthritis.
Meier FM; Frerix M; Hermann W; Müller-Ladner U
Immunotherapy; 2013 Sep; 5(9):955-74. PubMed ID: 23998731
[TBL] [Abstract][Full Text] [Related]
2. Rheumatoid arthritis.
Scott DL; Wolfe F; Huizinga TW
Lancet; 2010 Sep; 376(9746):1094-108. PubMed ID: 20870100
[TBL] [Abstract][Full Text] [Related]
3. Specific therapy to regulate inflammation in rheumatoid arthritis: molecular aspects.
García-Hernández MH; González-Amaro R; Portales-Pérez DP
Immunotherapy; 2014; 6(5):623-36. PubMed ID: 24896630
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
[TBL] [Abstract][Full Text] [Related]
5. Leflunomide for rheumatoid arthritis.
Drug Ther Bull; 2000 Jul; 38(7):52-4. PubMed ID: 11027115
[TBL] [Abstract][Full Text] [Related]
6. Effects of double filtration plasmapheresis, leflunomide, and methotrexate on inflammatory changes found through magnetic resonance imaging in early rheumatoid arthritis.
Yu X; Wang L; Xu P; Lu W; Lan G; Ping L; Wang X; Tian J; Liu J
J Rheumatol; 2012 Jun; 39(6):1171-8. PubMed ID: 22505700
[TBL] [Abstract][Full Text] [Related]
7. Rheumatoid arthritis: an overview of new and emerging therapies.
Doan T; Massarotti E
J Clin Pharmacol; 2005 Jul; 45(7):751-62. PubMed ID: 15951465
[TBL] [Abstract][Full Text] [Related]
8. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.
Schiff MH; Whelton A
Semin Arthritis Rheum; 2000 Dec; 30(3):196-208. PubMed ID: 11124283
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment.
Smith MD; Weedon H; Papangelis V; Walker J; Roberts-Thomson PJ; Ahern MJ
Rheumatology (Oxford); 2010 May; 49(5):862-75. PubMed ID: 20147446
[TBL] [Abstract][Full Text] [Related]
10. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
[TBL] [Abstract][Full Text] [Related]
11. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
Sesin CA; Bingham CO
Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
[TBL] [Abstract][Full Text] [Related]
12. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
[TBL] [Abstract][Full Text] [Related]
13. [Therapy of rheumatoid arthritis (chronic polyarthritis)].
Villiger PM; Stucki G
Praxis (Bern 1994); 1996 Sep; 85(37):1102-7. PubMed ID: 8927885
[TBL] [Abstract][Full Text] [Related]
14. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.
Schoels M; Kapral T; Stamm T; Smolen JS; Aletaha D
Ann Rheum Dis; 2007 Aug; 66(8):1059-65. PubMed ID: 17307765
[TBL] [Abstract][Full Text] [Related]
15. Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis.
Nandi P; Kingsley GH; Scott DL
Curr Opin Rheumatol; 2008 May; 20(3):251-6. PubMed ID: 18388514
[TBL] [Abstract][Full Text] [Related]
16. DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
Simon LS
Int J Clin Pract; 2000 May; 54(4):243-9. PubMed ID: 10912314
[TBL] [Abstract][Full Text] [Related]
17. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers.
Kraan MC; Reece RJ; Barg EC; Smeets TJ; Farnell J; Rosenburg R; Veale DJ; Breedveld FC; Emery P; Tak PP
Arthritis Rheum; 2000 Aug; 43(8):1820-30. PubMed ID: 10943872
[TBL] [Abstract][Full Text] [Related]
18. Are biological targets the final goal for rheumatoid arthritis therapy?
Sharma P; Pathak K
Expert Opin Biol Ther; 2012 Dec; 12(12):1611-22. PubMed ID: 22954024
[TBL] [Abstract][Full Text] [Related]
19. Immunological therapies for rheumatoid arthritis.
Edwards CJ
Br Med Bull; 2005; 73-74():71-82. PubMed ID: 16174791
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics in rheumatoid arthritis.
Ranganathan P
Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
